Shom Goel

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer

Lestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T Stump, Michael Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan

Journal article  |  2023  |  JOURNAL OF EXPERIMENTAL MEDICINE

We performed single-cell RNA-sequencing and T cell receptor clonotype tracking of breast and ovarian cancer patients treated with ..

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2

Shom Goel, Antoinette R Tan, Hope S Rugo, Philippe Aftimos, Zoran Andric, Andrew Beelen, Jingshan Zhang, John S Yi, Rajesh Malik, Joyce O'Shaughnessy

Journal article  |  2022  |  FUTURE ONCOLOGY

Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic chemotherapy remains the backbone of treatmen..

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

Seth A Wander, Neil O'Brien, Lacey M Litchfield, Declan O'Dea, Claudia Morato Guimaraes, Dennis J Slamon, Shom Goel

Journal article  |  2022  |  ONCOLOGIST

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients wi..

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer

Sonia Pernas, Jennifer L Guerriero, Sergey Naumenko, Shom Goel, Meredith M Regan, Jiani Hu, Beth T Harrison, Filipa Lynce, Nancy U Lin, Ann Partridge, Aki Morikawa, John Hutchinson, Elizabeth A Mittendorf, Artem Sokolov, Beth Overmoyer

Journal article  |  2022  |  THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

BACKGROUND: Inflammatory breast cancer (IBC) is a rare and understudied disease, with 40% of cases presenting with human epidermal..

Targeting CDK4 and CDK6 in cancer

Shom Goel, Johann S Bergholz, Jean J Zhao

Journal article  |  2022  |  NATURE REVIEWS CANCER

Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular transition into S phase and are important for the ini..

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

April C Watt, Shom Goel

Journal article  |  2022  |  BREAST CANCER RESEARCH

Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an established standard of care for patients with ..

Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study

Xavier Tekpli, Shom Goel, Barbro Holm, Lars-Egil Fallang, Laurens Cornelus Reitsma, Stephanie Beate Geisler, Hilde Presterud Ødegård, Cathrine Bergquist Fosskaug, Ida Caroline Lindem, Manouchehr Seyedzadeh, Jonn Terje Geitung, Joana Reis, Kjell Inge Gjesdal, Unn-Cathrin Buvarp, Marie Loeng, Kristine Kleivi Sahlberg, Alina Carmen Porojnicu, Helle Kristine Skjerven, Andliena Tahiri, Shakila Jabeen, et al.

Conference Proceedings  |  2022  |  Cancer Research

Abstract Background: The introduction of CDK4/6 inhibitors has been one of the most pivotal breakthroughs in breast..

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Khalid El Bairi, Harry R Haynes, Elizabeth Blackley, Susan Fineberg, Jeffrey Shear, Sophia Turner, Juliana Ribeiro de Freitas, Daniel Sur, Luis Claudio Amendola, Masoumeh Gharib, Amine Kallala, Indu Arun, Farid Azmoudeh-Ardalan, Luciana Fujimoto, Luz F Sua, Shi-Wei Liu, Huang-Chun Lien, Pawan Kirtani, Marcelo Balancin, Hicham El Attar, et al.

Journal article  |  2021  |  NPJ BREAST CANCER

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings..

Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation

Max Heckler, Lestat R Ali, Eleanor Clancy-Thompson, Li Qiang, Katherine S Ventre, Patrick Lenehan, Kevin Roehle, Adrienne Luoma, Kelly Boelaars, Vera Peters, Julia McCreary, Tamara Boschert, Eric S Wang, Shengbao Suo, Francesco Marangoni, Thorsten R Mempel, Henry W Long, Kai W Wucherpfennig, Michael Dougan, Nathanael S Gray, et al.

Journal article  |  2021  |  CANCER DISCOVERY

CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in m..

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx(R) Digital Spatial Profiler

Helga Bergholtz, Jodi M Carter, Alessandra Cesano, Maggie Chon U Cheang, Sarah E Church, Prajan Divakar, Christopher A Fuhrman, Shom Goel, Jingjing Gong, Jennifer L Guerriero, Margaret L Hoang, E Shelley Hwang, Hellen Kuasne, Jinho Lee, Yan Liang, Elizabeth A Mittendorf, Jessica Perez, Aleix Prat, Lajos Pusztai, Jason W Reeves, et al.

Journal article  |  2021  |  CANCERS

Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Under..